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et al., 2006) to stick with a particular mode
of movement irrespective of the external
environment, but in general, the ability to
switch between modes of movement
gives cells the greatest chance to react
to a broad and changeable range of con-
ditions.
Although Sanz-Moreno et al. (2008)
have made a number of important discov-
eries, their findings also raise additional
questions. Given the large number of
RhoGEFs and RhoGAPs, it is notable
that DOCK3/NEDD9 and ARHGAP22 are
sufficient for Rac activation and inactiva-
tion, respectively. It remains to be deter-
mined whether these proteins also con-
tribute to the movement of other types of
tumor cells. RhoA is highly active in the
amoeboid mode of movement, but the
RhoGEF (or multiple RhoGEFs) responsi-
ble has yet to be identified. More chal-
lenging will be working out the mecha-
nisms responsible for the inhibition of
Rac activity by Rho signaling and vice
versa. Although ROCK activation was suf-
ficient to repress Rac activity, this does
not appear to work via direct phosphory-
lation of ARHGAP22 by ROCK; instead,
actin-myosin contractility regulates
ARHGAP22-mediated inactivation of Rac
by unknownmeans. Similarly, the locus of
WAVE2-mediated repression of MLC2
phosphorylation has not been identified;
although regulation of RhoA activity
seems most likely, it is also possible that
the effect occurs directly on MLC2. Given
that WAVE2 is a single component of
a large multiprotein complex, it will be in-
teresting to determine whether this effect
ismediated by the individual protein or the
entire WAVE2 complex. It has recently
been shown that depletion of the WAVE
complex protein Brk1 induces blebbing,
suggesting that a functional complex is
required for RhoA suppression (Derivery
et al., 2008).
These observations also impact upon
potential antimetastatic drug therapies—
if one mode of motility is targeted, for
example by inhibiting protease or ROCK
activity, then tumor cells may switch to
the other mode. Therefore, it would be de-
sirable to target proteins that may contrib-
ute to both modes of movement, for ex-
ample LIM kinases (Scott and Olson,
2007), to increase the likelihood of suc-
cessfully blocking the spread of cancer
cells.
REFERENCES
Bos, J.L., Rehmann, H., and Wittinghofer, A.
(2007). Cell 129, 865–877.
Derivery, E., Fink, J., Martin, D., Houdusse, A., Piel,
M., Stradal, T.E., Louvard, D., and Gautreau, A.
(2008). PLoS ONE 3, e2462.
Hanahan, D., and Weinberg, R.A. (2000). Cell 100,
57–70.
Kim, M., Gans, J.D., Nogueira, C., Wang, A., Paik,
J.H., Feng, B., Brennan, C., Hahn, W.C., Cordon-
Cardo, C., Wagner, S.N., et al. (2006). Cell 125,
1269–1281.
Olson, M.F., and Sahai, E. (2008). Clin. Exp. Metas-
tasis. Published online May 23, 2008. 10.1007/
s10585-008-9174-2.
Sahai, E., and Marshall, C.J. (2003). Nat. Cell Biol.
5, 711–719.
Sanz-Moreno, V., Gadea, G., Ahn, J., Paterson, H.,
Marra, P., Pinner, S., Sahai, E., and Marshall, C.J.
(2008). Cell 135, 510–523.
Scott, R.W., and Olson, M.F. (2007). J. Mol. Med.
85, 555–568.
Wolf, K., Mazo, I., Leung, H., Engelke, K., von An-
drian, U.H., Deryugina, E.I., Strongin, A.Y.,
Brocker, E.-B., and Friedl, P. (2003). J. Cell Biol.
160, 267–277.
Wyckoff, J.B., Pinner, S.E., Gschmeissner, S.,
Condeelis, J.S., and Sahai, E. (2006). Curr. Biol.
16, 1515–1523.
Cancer Cell
PreviewsGlycogen Synthase Kinase-3 and Cancer:
Good Cop, Bad Cop?
Satish Patel1 and Jim Woodgett1,*
1Samuel Lunenfeld Research Institute, Toronto, ON M5G 1X5, Canada
*Correspondence: woodgett@lunenfeld.ca
DOI 10.1016/j.ccr.2008.10.013
Dogma held that inhibition of the pleiotropic protein kinase glycogen synthase kinase-3 (GSK-3) was procar-
cinogenic due to its natural repression of b-catenin. Now, Wang et al. have found the reverse in certain leu-
kemias, possibly paving the way for small-molecule GSK-3 inhibitors as selective anticancer agents.Glycogen synthase kinase-3 (GSK-3)
was originally identified and later en-
shrined as a member of the insulin-sig-
naling pathway responsible for phos-
phorylation and inactivation of glycogen
synthase, a major regulatory enzyme of
glycogen metabolism. But it was soon
recognized that this kinase paints with
far broader strokes, influencing pro-cesses that govern cell metabolism, po-
larity, transcription, cell-cycle division,
apoptosis, development, and cell fate. In
mammals, GSK-3 exists as two isoforms,
encoded by separate genes. GSK-3a
(51 kDa) and GSK-3b (47 kDa) are highly
conserved and widely expressed kinases
that share 98% sequence identity within
their catalytic domains (Doble and Wood-Cancer Cell 14,gett, 2003). While structurally related,
these isoforms are not functionally equiv-
alent.
Unlike most protein kinases, GSK-3 is
active under resting conditions and is rap-
idly inhibited by diverse stimuli. For exam-
ple, insulin, via PI3K/Akt/PKB, induces the
inactivation of GSK-3. Many of its cellular
targets are held in an inactive stateNovember 4, 2008 ª2008 Elsevier Inc. 351
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Previewsthrough inhibitory phosphorylation. Phos-
phorylation by GSK-3 can also promote
the ubiquitination and degradation of tar-
get proteins. Dysregulation of GSK-3, or
the pathways that control it, has been
implicated in various human diseases
such as muscle hypertrophy, diabetes,
cancer, bipolar mood disorder, schizo-
phrenia, and neurodegenerative diseases
(Martinez, 2008).
The therapeutic potential of GSK-3 in-
hibitors in these disease states has been
actively pursued, and several potent
chemical inhibitors of GSK-3 have been
developed, most of which are ATP com-
petitive and do not discriminate between
GSK-3a and GSK-3b. Administration of
these inhibitors improves glucose ho-
meostasis and insulin action in rodent
models of diabetes and obesity, and
there is evidence that the inhibitors may
be useful for conditions associated with
inflammation such as ischemia, sepsis,
and colitis as well as neurodegenerative
accumulation of hyperphosphorylated
tau (Martinez, 2008). Cumulatively, these
data suggest a promising future for
GSK-3 antagonists. However, their prog-
ress into clinical trials has been clouded
by the concern that inhibition of GSK-3
may promote oncogenesis. GSK-3 is
a key suppressor of the Wnt, Hedgehog,
and Notch pathways that control cellular
fate determination and stem cell mainte-
nance. Within these pathways, GSK-3
serves to phosphorylate the pro-onco-
genic molecules b-catenin, c-Myc, and
c-Jun, targeting them for degradation
or inactivation and thereby inhibiting
proliferation and self-renewal. However,
these pathways are commonly deregu-
lated in human cancers, and further-
more, gain-of-function mutations in
these three proteins that interfere with
GSK-3 inhibition have been found in
cancers of the skin, colon, prostate,
and liver (Polakis, 2007). Thus, GSK-3 in-
hibition could mimic ectopic signaling of
these pathways and promote tumorigen-
esis. However, no direct in vivo evidence
has indicated that such a phenomenon
occurs upon administration of GSK-3 in-
hibitors. Rather, recent studies in pros-
tate, pancreatic, and colorectal cancer
cell lines indicate that GSK-3 inhibitors
lead to significant reduction in cell
growth and proliferation (Martinez,
2008; Ougolkov et al., 2006), suggesting
that inhibiting GSK-3 may actually be352 Cancer Cell 14, November 4, 2008 ª200beneficial for the treatment of specific
cancers.
In a recent study, Wang et al. (2008)
have provided strong evidence demon-
strating that GSK-3 activity is essential
for maintenance of a subset of leukemias
driven by the translocation of the MLL
(mixed-lineage leukemia) proto-onco-
gene. MLL rearrangements are found in
approximately 10% of human leukemias,
with >70% frequency of occurrence in
infant leukemia. Over 50 different translo-
cation fusion partners have been identi-
fied. Patients with MLL fusions often
have a poor clinical outcome, and thus
much effort has focused on seeking
new treatments (Krivtsov and Armstrong,
2007).
Using a pharmacological screen,
Wang et al. (2008) found that selective in-
hibitors of GSK-3 (GSK-3 IX, SB216763,
and alsterpaullone) specifically inhibited
the growth of human MLL leukemia but
not other leukemia cells. In addition,
GSK-3 inhibitors reduced clonogenic po-
tential and proliferation of MLL-trans-
duced murine myeloid or B cell progeni-
tors. Importantly, normal primary myeloid
progenitors and progenitors transduced
by non-MLL fusions displayed little sen-
sitivity todrugtreatment.Theauthorsdem-
onstrated that this inhibitor effect was
indeed mediated by GSK-3, as genetic
ablation of GSK-3b and shRNA-medi-
ated knockdown of GSK-3a phenocop-
ied the reduced self-renewing capacity
of MLL-transformed progenitors in vitro
and leukemogenesis in transplanted
mice. The Wang et al. study also demon-
strated that both GSK-3a and GSK-3b
play redundant roles in maintenance of
MLL-transformed leukemias and that
a >75% reduction in kinase activity is re-
quired to invoke impairment of leukemo-
genicity. This resembles the functionally
redundant role of GSK-3 within the Wnt
pathway in maintaining low cytoplasmic
levels of b-catenin in resting cells, such
that removal of at least 3 of the 4 GSK-3
alleles is required for any significant Wnt
signaling (Doble et al., 2007). Mechanisti-
cally, GSK-3 inhibitors expectedly in-
creased b-catenin levels. While the
extent of b-catenin stabilization was simi-
lar in both non-MLL and human MLL
leukemia cell lines, the researchers ob-
served that inhibition of GSK-3 induced
expression of the cyclin-dependent
kinase inhibitor p27Kip1 in only MLL-8 Elsevier Inc.transformed cells. Furthermore, shRNA-
p27Kip1 prevented GSK-3 inhibitor-in-
duced growth arrest of MLL-leukemic
cells (Figure 1).
These findings represent new and
contrasting insights into the role of
GSK-3 as a negative regulator of prolifer-
ation and self-renewal. GSK-3 has been
shown to modulate hematopoietic stem
cell (HSC) activity in vivo, suggesting
that administration of GSK-3 inhibitors
may directly enhance the repopulating
capacity of transplanted HSCs (Holmes
et al., 2008). Recent data indicate that
certain leukemias are maintained by
a population of self-renewing leukemia
stem cells (LSCs) and that they originate
from transformed HSCs and committed
myeloid progenitors. A major concern is
whether LSCs can be specifically tar-
geted without affecting normal HSCs.
Wang et al. (2008) provide compelling
evidence that inhibitors of GSK-3 could
indeed be useful in specifically targeting
the LSC population with MLL rearrange-
ments without perturbing the normal
HSC compartment. There are some in-
teresting questions that arise from their
studies. First, why are MLL-rearranged
leukemia cells, but not other leukemia
cells, vulnerable to GSK-3 inhibitors?
Wang et al. show that the abundance
of the MLL fusion oncogenes is not al-
tered by GSK-3 inhibition, but the mech-
anism by which these cells are sensitized
remains unclear, as does the molecular
means by which GSK-3 influences
p27Kip1. Recently, it was shown that
a set of non-MLL leukemia cells ex-
hibited overexpression of c-Myc and
that the capacity of GSK-3 to associate
and target Myc for degradation was re-
duced. This ‘‘GSK-3 resistance’’ may of-
fer an explanation as to why non-MLL
cells are insensitive to GSK-3 inhibitors
(Malempati et al., 2006). Second, what
is the molecular mechanism by which
GSK-3 supports MLL-induced oncogen-
esis? The authors allude to the existence
of an Akt/GSK-3/p27Kip1 pathway within
these cells. They show that a constitu-
tively active Akt mutant suppresses
MLL-positive cells and this is abolished
by coexpression of a GSK-3 mutant
that can no longer be phosphorylated
and/or inhibited by Akt (Figure 1). It
would be of interest to determine
whether MLL-induced leukemogenesis
can occur in GSK-3a/b knockin mice
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PreviewsFigure 1. Dependence of MLL-Leukemic Cells on GSK-3 Activity for Proliferation
The model of Wang et al. (2008) suggests that GSK-3 supports the maintenance ofMLL leukemia cells by
promoting continuous degradation of the cyclin-dependent kinase inhibitor p27Kip1. Various strategies to
inactivate GSK-3 result in stabilization of p27Kip1, which invokes subsequent growth arrest inMLL but not
non-MLL leukemic or normal cells.expressing non-Akt-inhibitable mutants
of GSK-3 (McManus et al., 2005) and, if
so, the status of p27Kip1 expression in
the tumor cells. Third, and most impor-
tantly, what are the long-term effects of
high-level GSK-3 inhibition as a therapy
for MLL leukemias? This new study rai-
ses the possibility that activation of
p27Kip1 and its growth-inhibitory action
will trump pro-oncogenic effects on pro-teins such as b-catenin. Wang et al. also
demonstrated that exposure of animals
with MLL-like leukemia to lithium, which
inhibits GSK-3, prolonged the survival
of the treated mice by 40%–50%. For
decades, lithium has been widely used
for the treatment of bipolar disorder,
and there has been no evidence that
these patients have increased incidence
of cancers. Indeed, mice that have en-Cancer Cell 14,hancedWnt signaling andmultiple intesti-
nal polyps due to mutation of one copy of
Apc do not exhibit further increased num-
bers of polyps when treated with lithium
(reviewed in Doble and Woodgett, 2003).
Thus, it appears that despite initial con-
cerns that long-term use of GSK-3 inhibi-
tors might promote oncogenesis, evi-
dence is accumulating to suggest that
these drugs may in fact be effective in
the treatment of certain cancers.
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